{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T01:32:40Z","timestamp":1783128760812,"version":"3.54.6"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammation"],"DOI":"10.1007\/s10753-025-02281-w","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T14:42:31Z","timestamp":1743777751000},"page":"3519-3528","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["CRISPR\/Cas9-Mediated Knockout and Overexpression Studies Unveil the Role of PD-L1 in Immune Modulation in a Psoriasis-like Mouse Model"],"prefix":"10.1007","volume":"48","author":[{"given":"Chunjie","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxi","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiankun","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoya","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Kuai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Ru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seokgyeong","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"key":"2281_CR1","doi-asserted-by":"crossref","unstructured":"Greb, J.E., A.M. Goldminz, J.T. Elder, M.G. Lebwohl, D.D. Gladman, J.J. Wu, N.N, et al. 2016. Psoriasis. Nature Reviews. Disease Primers 2: 16082","DOI":"10.1038\/nrdp.2016.82"},{"key":"2281_CR2","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","volume":"386","author":"WH Boehncke","year":"2015","unstructured":"Boehncke, W.H., and M.P. Sch\u00f6n. 2015. Psoriasis. Lancet (London, England) 386: 983\u2013994.","journal-title":"Lancet (London, England)"},{"key":"2281_CR3","doi-asserted-by":"publisher","first-page":"850108","DOI":"10.3389\/fgene.2022.850108","volume":"13","author":"JK Song","year":"2022","unstructured":"Song, J.K., Y. Zhang, X.Y. Fei, Y.R. Chen, Y. Luo, J.S. Jiang, et al. 2022. Classification and biomarker gene selection of pyroptosis-related gene expression in psoriasis using a random forest algorithm. Frontiers in Genetics 13: 850108.","journal-title":"Frontiers in Genetics"},{"key":"2281_CR4","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1111\/imm.13843","volume":"173","author":"G Deng","year":"2024","unstructured":"Deng, G., Y. Zhang, J. Song, Y. Zhang, Q. Zheng, Y. Luo, et al. 2024. The role and therapeutic strategies for tissue-resident memory T cells, central memory T cells, and effector memory T cells in psoriasis. Immunology 173: 470\u2013480.","journal-title":"Immunology"},{"key":"2281_CR5","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1016\/S0142-9612(01)00021-7","volume":"22","author":"SR Hong","year":"2001","unstructured":"Hong, S.R., S.J. Lee, J.W. Shim, Y.S. Choi, Y.M. Lee, K.W. Song, et al. 2001. Study on gelatin-containing artificial skin IV: A comparative study on the effect of antibiotic and EGF on cell proliferation during epidermal healing. Biomaterials 22: 2777\u20132783.","journal-title":"Biomaterials"},{"key":"2281_CR6","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.jcyt.2018.07.003","volume":"20","author":"H Dai","year":"2018","unstructured":"Dai, H., Y. Zhou, C. Tong, Y. Guo, F. Shi, Y. Wang, and P. Shen. 2018. Restoration of CD3+CD56+ cell level improves skin lesions in severe psoriasis: A pilot clinical study of adoptive immunotherapy for patients with psoriasis using autologous cytokine-induced killer cells. Cytotherapy 20: 1155\u20131163.","journal-title":"Cytotherapy"},{"key":"2281_CR7","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/j.1440-0960.2006.00262.x","volume":"47","author":"MR Lee","year":"2006","unstructured":"Lee, M.R., and A.J. Cooper. 2006. Immunopathogenesis of psoriasis. The Australasian Journal of Dermatology 47: 151\u2013159.","journal-title":"The Australasian Journal of Dermatology"},{"key":"2281_CR8","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1111\/j.1365-4632.2004.02528.x","volume":"45","author":"R P\u00e9rez-Lorenzo","year":"2006","unstructured":"P\u00e9rez-Lorenzo, R., L. N\u00fa\u00f1ez-Oreza, P. Garma-Quen, E. L\u00f3pez-Pacheco, and G. Bricaire-Bricaire. 2006. Peripheral blood mononuclear cells proliferation and Th1\/Th2 cytokine production in response to streptococcal M protein in psoriatic patients. International journal of dermatology 45: 1365\u20134632.","journal-title":"International journal of dermatology"},{"key":"2281_CR9","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/978-1-4419-7913-1_13","volume":"706","author":"Hsi-Hsien Lin","year":"2010","unstructured":"Lin, Hsi-Hsien., Martin Stacey, Joan Stein-Streilein, and Siamon Gordon. 2010. F4\/80: The macrophage-specific adhesion-GPCR and its role in immunoregulation. Advances in Experimental Medicine and Biology 706: 149\u2013156.","journal-title":"Advances in Experimental Medicine and Biology"},{"key":"2281_CR10","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.intimp.2014.12.032","volume":"24","author":"Y Sun","year":"2015","unstructured":"Sun, Y., J. Zhang, R. Huo, T. Zhai, H. Li, P. Wu, et al. 2015. Paeoniflorin inhibits skin lesions in imiquimod-induced psoriasis-like mice by downregulating inflammation. International Immunopharmacology 24: 392\u2013399.","journal-title":"International Immunopharmacology"},{"key":"2281_CR11","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1172\/JCI200421032","volume":"114","author":"KS Chan","year":"2004","unstructured":"Chan, K.S., S. Sano, K. Kiguchi, J. Anders, N. Komazawa, J. Takeda, and J. DiGiovanni. 2004. Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. The Journal of clinical investigation 114: 720\u2013728.","journal-title":"The Journal of clinical investigation"},{"key":"2281_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nm1162","volume":"11","author":"S Sano","year":"2005","unstructured":"Sano, S., K.S. Chan, S. Carbajal, J. Clifford, M. Peavey, K. Kiguchi, et al. 2005. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nature Medicine 11: 43\u201349.","journal-title":"Nature Medicine"},{"key":"2281_CR13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jare.2020.09.002","volume":"30","author":"M Zhou","year":"2021","unstructured":"Zhou, M., H. Xu, D. Zhang, C. Si, X. Zhou, H. Zhao, et al. 2021. Decreased PIBF1\/IL6\/p-STAT3 during the mid-secretory phase inhibits human endometrial stromal cell proliferation and decidualization. Journal of Advanced Research 30: 15\u201325.","journal-title":"Journal of Advanced Research"},{"key":"2281_CR14","doi-asserted-by":"crossref","unstructured":"Brandt, D., M. Sergon, S. Abraham, K. M\u00e4bert, and C.M. Hedrich. 2017. TCR+CD3+CD4-CD8- effector T cells in psoriasis. Clinical Immunology (Orlando, Fla.) 181: 51\u201359.","DOI":"10.1016\/j.clim.2017.06.002"},{"key":"2281_CR15","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1046\/j.1365-2249.2002.01721.x","volume":"127","author":"A Koreck","year":"2002","unstructured":"Koreck, A., A. Sur\u00e1nyi, B.J. Sz\u00f6ny, A. Farkas, Z. Bata-Cs\u00f6rg\u00f6, L. Kem\u00e9ny, and A. Dobozy. 2002. CD3+CD56+ NK T cells are significantly decreased in the peripheral blood of patients with psoriasis. Clinical and Experimental Immunology 127: 176\u2013182.","journal-title":"Clinical and Experimental Immunology"},{"key":"2281_CR16","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/cei.13106","volume":"192","author":"J Niu","year":"2018","unstructured":"Niu, J., Z. Zhai, F. Hao, Y. Zhang, Z. Song, and H. Zhong. 2018. Dissection of a circulating CD3+ CD20+ T cell subpopulation in patients with psoriasis. Clinical and Experimental Immunology 192: 206\u2013212.","journal-title":"Clinical and Experimental Immunology"},{"key":"2281_CR17","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","volume":"11","author":"Y Ishida","year":"1992","unstructured":"Ishida, Y., Y. Agata, K. Shibahara, and T. Honjo. 1992. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. The EMBO journal 11: 3887\u20133895.","journal-title":"The EMBO journal"},{"key":"2281_CR18","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.currproblcancer.2017.10.003","volume":"41","author":"D Voudouri","year":"2017","unstructured":"Voudouri, D., V. Nikolaou, K. Laschos, A. Charpidou, N. Soupos, L. Triantafyllopoulou, et al. 2017. Anti-PD1\/PDL1 induced psoriasis. Current Problems in Cancer 41: 407\u2013412.","journal-title":"Current Problems in Cancer"},{"key":"2281_CR19","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s00403-015-1588-5","volume":"307","author":"DS Kim","year":"2015","unstructured":"Kim, D.S., J.H. Je, S.H. Kim, D. Shin, T.G. Kim, D.Y. Kim, et al. 2015. Programmed death-ligand 1, 2 expressions are decreased in the psoriatic epidermis. Archives of Dermatological Research 307: 531\u2013538.","journal-title":"Archives of Dermatological Research"},{"key":"2281_CR20","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1016\/j.jaci.2015.11.021","volume":"137","author":"JH Kim","year":"2016","unstructured":"Kim, J.H., Y.J. Choi, B.H. Lee, M.Y. Song, C.Y. Ban, J. Kim, et al. 2016. Programmed cell death ligand 1 alleviates psoriatic inflammation by suppressing IL-17A production from programmed cell death 1-high T cells. The Journal of Allergy and Clinical Immunology 137: 1466\u20131476.","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"2281_CR21","doi-asserted-by":"crossref","unstructured":"van der Fits, L., S. Mourits, J.S.A. Voerman, M. Kant, L. Boon, J. D. Laman, et al. 2009. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23\/IL-17 axis. Journal of Immunology (Baltimore, Md.: 1950) 182: 5836\u20135845.","DOI":"10.4049\/jimmunol.0802999"},{"key":"2281_CR22","doi-asserted-by":"crossref","unstructured":"Lin, Z.C., P.W. Hsieh, T.L. Hwang, C.Y. Chen, C.T. Sung, and J.Y. Fang. 2018. Topical application of anthranilate derivatives ameliorates psoriatic inflammation in a mouse model by inhibiting keratinocyte-derived chemokine expression and neutrophil infiltration. FASEB journal: official publication of the Federation of American Societies for Experimental Biology: fj201800354.","DOI":"10.1096\/fj.201800354"},{"key":"2281_CR23","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1093\/aob\/mcq243","volume":"107","author":"W Strzalka","year":"2011","unstructured":"Strzalka, W., and A. Ziemienowicz. 2011. Proliferating cell nuclear antigen (PCNA): A key factor in DNA replication and cell cycle regulation. Annals of Botany 107: 1127\u20131140.","journal-title":"Annals of Botany"},{"key":"2281_CR24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jdermsci.2012.11.002","volume":"69","author":"AM Goldminz","year":"2013","unstructured":"Goldminz, A.M., S.C. Au, N. Kim, A.B. Gottlieb, and P.F. Lizzul. 2013. NF-\u03baB: An essential transcription factor in psoriasis. Journal of Dermatological Science 69: 89\u201394.","journal-title":"Journal of Dermatological Science"},{"key":"2281_CR25","doi-asserted-by":"publisher","first-page":"075804","DOI":"10.3389\/fimmu.2022.1075804","volume":"13","author":"T Roy","year":"2023","unstructured":"Roy, T., S. Banang-Mbeumi, S.T. Boateng, E.M. Ruiz, R.N. Chamcheu, L. Kang, et al. 2023. Dual targeting of mTOR\/IL-17A and autophagy by fisetin alleviates psoriasis-like skin inflammation. Frontiers in immunology 13: 075804.","journal-title":"Frontiers in immunology"},{"key":"2281_CR26","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1182\/blood-2009-08-238543","volume":"115","author":"D Rajagopal","year":"2010","unstructured":"Rajagopal, D., C. Paturel, Y. Morel, S. Uematsu, S. Akira, and S.S. Diebold. 2010. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists. Blood 115: 1949\u20131957.","journal-title":"Blood"},{"key":"2281_CR27","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1001\/archderm.140.12.1490","volume":"140","author":"M Gilliet","year":"2004","unstructured":"Gilliet, M., C. Conrad, M. Geiges, A. Cozzio, W. Th\u00fcrlimann, G. Burg, et al. 2004. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Archives of Dermatology 140: 1490\u20131495.","journal-title":"Archives of Dermatology"},{"key":"2281_CR28","doi-asserted-by":"crossref","unstructured":"Casanova, J.L., J.D. MacMicking, and C.F. Nathan. 2024. Interferon-\u03b3 and infectious diseases: Lessons and prospects. Science (New York, N.Y.) 384: eadl2016.","DOI":"10.1126\/science.adl2016"},{"key":"2281_CR29","doi-asserted-by":"publisher","first-page":"100116","DOI":"10.1016\/j.xjidi.2022.100116","volume":"2","author":"D Tian","year":"2022","unstructured":"Tian, D., and Y. Lai. 2022. The Relapse of Psoriasis: Mechanisms and Mysteries. JID innovations: Skin science from molecules to population health 2: 100116.","journal-title":"JID innovations: Skin science from molecules to population health"},{"key":"2281_CR30","doi-asserted-by":"publisher","first-page":"e2117523119","DOI":"10.1073\/pnas.2117523119","volume":"119","author":"J Zhou","year":"2022","unstructured":"Zhou, J., J. Zhang, L. Tao, K. Peng, Q. Zhang, K. Yan, et al. 2022. Up-regulation of BTN3A1 on CD14+ cells promotes V\u03b39V\u03b42 T cell activation in psoriasis. Proceedings of the National Academy of Sciences of the United States of America 119: e2117523119.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"2281_CR31","doi-asserted-by":"publisher","first-page":"C272","DOI":"10.1152\/ajpcell.00314.2019","volume":"318","author":"X Miao","year":"2020","unstructured":"Miao, X., Y. Xiang, W. Mao, Y. Chen, Q. Li, and B. Fan. 2020. TRIM27 promotes IL-6-induced proliferation and inflammation factor production by activating STAT3 signaling in HaCaT cells. American Journal of Physiology. Cell Physiology 318: C272\u2013C281.","journal-title":"American Journal of Physiology. Cell Physiology"},{"key":"2281_CR32","doi-asserted-by":"publisher","first-page":"e20191397","DOI":"10.1084\/jem.20191397","volume":"217","author":"I Prinz","year":"2020","unstructured":"Prinz, I., I. Sandrock, and U. Mrowietz. 2020. Interleukin-17 cytokines: Effectors and targets in psoriasis-A breakthrough in understanding and treatment. The Journal of Experimental Medicine 217: e20191397.","journal-title":"The Journal of Experimental Medicine"},{"key":"2281_CR33","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.immuni.2007.05.016","volume":"27","author":"MJ Butte","year":"2007","unstructured":"Butte, M.J., M.E. Keir, T.B. Phamduy, A.H. Sharpe, and G.J. Freeman. 2007. Programmed death-1 ligand 1 interacts specifically with the B7\u20131 costimulatory molecule to inhibit T cell responses. Immunity 27: 111\u2013122.","journal-title":"Immunity"},{"key":"2281_CR34","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1084\/jem.20051776","volume":"203","author":"ME Keir","year":"2006","unstructured":"Keir, M.E., S.C. Liang, I. Guleria, Y.E. Latchman, A. Qipo, L.A. Albacker, et al. 2006. Tissue expression of PD-L1 mediates peripheral T cell tolerance. The Journal of Experimental Medicine 203: 883\u2013895.","journal-title":"The Journal of Experimental Medicine"},{"key":"2281_CR35","doi-asserted-by":"publisher","first-page":"632414","DOI":"10.3389\/fphar.2021.632414","volume":"12","author":"L Kuai","year":"2021","unstructured":"Kuai, L., Y. Luo, K. Qu, Y. Ru, Y. Luo, X. Ding, et al. 2021. Transcriptomic analysis of the mechanisms for alleviating psoriatic dermatitis using taodan granules in an imiquimod-induced psoriasis-like mouse model. Frontiers in Pharmacology 12: 632414.","journal-title":"Frontiers in Pharmacology"},{"key":"2281_CR36","doi-asserted-by":"crossref","unstructured":"Song, J., J. Jiang, L. Kuai, Y. Luo, M. Xing, Y. Luo et al. 2022. TMT-based proteomics analysis reveals the protective effect of Jueyin granules on imiquimod-induced psoriasis mouse model by causing autophagy. Phytomedicine: International Journal of Phytotherapy and Phytopharmacology 96: 153846.","DOI":"10.1016\/j.phymed.2021.153846"},{"key":"2281_CR37","doi-asserted-by":"crossref","unstructured":"D\u2019Addio, F., L.V. Riella, B.G. Mfarrej, L. Chabtini, L.T. Adams, M. Yeung, et al. 2011. The link between the PDL1 costimulatory pathway and Th17 in fetomaternal tolerance. Journal of Immunology (Baltimore, Md.: 1950) 187: 4530\u20134541.","DOI":"10.4049\/jimmunol.1002031"},{"key":"2281_CR38","doi-asserted-by":"crossref","unstructured":"Dulos, J., G.J. Carven, S.J. van Boxtel, S. Evers, L.J.A. Driessen-Engels, W. Hobo, et al. 2012. PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. Journal of Immunotherapy (Hagerstown, Md.: 1997) 35: 169\u2013178.","DOI":"10.1097\/CJI.0b013e318247a4e7"},{"key":"2281_CR39","doi-asserted-by":"publisher","first-page":"16073","DOI":"10.1073\/pnas.1315828110","volume":"110","author":"Y Rui","year":"2013","unstructured":"Rui, Y., T. Honjo, and S. Chikuma. 2013. Programmed cell death 1 inhibits inflammatory helper T-cell development through controlling the innate immune response. Proceedings of the National Academy of Sciences of the United States of America 110: 16073\u201316078.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"2281_CR40","doi-asserted-by":"crossref","unstructured":"Imai, Y., N. Ayithan, X. Wu, Y. Yuan, L. Wang, and S.T. Hwang. 2015. Cutting Edge: PD-1 Regulates Imiquimod-Induced Psoriasiform Dermatitis through Inhibition of IL-17A Expression by Innate \u03b3\u03b4-Low T Cells. Journal of Immunology (Baltimore, Md.: 1950) 195: 421\u2013425.","DOI":"10.4049\/jimmunol.1500448"},{"key":"2281_CR41","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1007\/s12026-020-09149-1","volume":"68","author":"B Li","year":"2020","unstructured":"Li, B., L. Huang, P. Lv, X. Li, G. Liu, Y. Chen, et al. 2020. The role of Th17 cells in psoriasis. Immunologic Research 68: 296\u2013309.","journal-title":"Immunologic Research"},{"key":"2281_CR42","doi-asserted-by":"crossref","unstructured":"Jia, H., T. Liu, Q. Yang, H. Zheng, S. Fu, J. Hong, et al. 2023. Tumor-derived PD-L1+ exosomes with natural inflammation tropism for psoriasis-targeted treatment. Bioconjugate Chemistry.","DOI":"10.1021\/acs.bioconjchem.3c00129"},{"key":"2281_CR43","doi-asserted-by":"publisher","first-page":"6767","DOI":"10.1038\/s41467-023-42477-y","volume":"14","author":"X Lu","year":"2023","unstructured":"Lu, X., L. Kuai, F. Huang, J. Jiang, J. Song, Y. Liu, et al. 2023. Single-atom catalysts-based catalytic ROS clearance for efficient psoriasis treatment and relapse prevention via restoring ESR1. Nature Communications 14: 6767.","journal-title":"Nature Communications"},{"key":"2281_CR44","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1016\/j.jid.2022.01.018","volume":"142","author":"L Kuai","year":"2022","unstructured":"Kuai, L., Y. Ru, Q.G. Zhu, S.Y. Yin, Y.Y. Li, M. Zhou, et al. 2022. Celastrol attenuates Psoriasiform inflammation by targeting the IRF1\/GSTM3 Axis. The Journal of Investigative Dermatology 142: 2281-2285.e11.","journal-title":"The Journal of Investigative Dermatology"},{"key":"2281_CR45","doi-asserted-by":"publisher","first-page":"113214","DOI":"10.1016\/j.jep.2020.113214","volume":"262","author":"L Kuai","year":"2020","unstructured":"Kuai, L., J.K. Song, R.X. Zhang, M. Xing, Y. Luo, Y. Ru, et al. 2020. Uncovering the mechanism of Jueyin granules in the treatment of psoriasis using network pharmacology. Journal of Ethnopharmacology 262: 113214.","journal-title":"Journal of Ethnopharmacology"},{"key":"2281_CR46","first-page":"422","volume":"15","author":"Y Chen","year":"2023","unstructured":"Chen, Y., Z. Zhang, Y. Zhang, J. Jiang, Y. Luo, X. Fei, et al. 2023. Gene set enrichment analysis and ingenuity pathway analysis to verify the impact of Wnt signaling in psoriasis treated with Taodan granules. American Journal of Translational Research 15: 422\u2013434.","journal-title":"American Journal of Translational Research"},{"key":"2281_CR47","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","volume":"398","author":"JM Sun","year":"2021","unstructured":"Sun, J.M., L. Shen, M.A. Shah, P. Enzinger, A. Adenis, T. Doi, et al. 2021. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): A randomised, placebo-controlled, phase 3 study. Lancet (London, England) 398: 759\u2013771.","journal-title":"Lancet (London, England)"},{"key":"2281_CR48","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes, J., D.W. Cescon, H.S. Rugo, Z. Nowecki, S. Im, M.M. Yusof, et al. 2020. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): A randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet (London, England) 396: 1817\u20131828.","journal-title":"Lancet (London, England)"},{"key":"2281_CR49","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/s41591-018-0134-3","volume":"24","author":"DR Gandara","year":"2018","unstructured":"Gandara, D.R., S.M. Paul, M. Kowanetz, E. Schleifman, W. Zou, Y. Li, et al. 2018. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nature Medicine 24: 1441\u20131448.","journal-title":"Nature Medicine"},{"key":"2281_CR50","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.21.01862","volume":"40","author":"JJ Zhao","year":"2022","unstructured":"Zhao, J.J., D.W.T. Yap, Y.H. Chan, B.K.J. Tan, C.B. Teo, N.L. Syn, et al. 2022. Low programmed death-ligand 1-expressing subgroup outcomes of first-line immune checkpoint inhibitors in gastric or esophageal adenocarcinoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 40: 392\u2013402.","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"2281_CR51","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ad.2020.05.017","volume":"113","author":"E S\u00e1nchez-Mart\u00ednez","year":"2022","unstructured":"S\u00e1nchez-Mart\u00ednez, E., M. S\u00e1ez-Bell\u00f3, S. Ochenduszko, and A. Mateu-Puchades. 2022. Psoriasis and anti-PD-1 and anti-PD-L1 immunotherapy: Three cases, a review of the literature, and a proposed management algorithm. Actas Dermo-Sifiliograficas 113: 427\u2013431.","journal-title":"Actas Dermo-Sifiliograficas"},{"key":"2281_CR52","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","volume":"83","author":"AN Geisler","year":"2020","unstructured":"Geisler, A.N., G.S. Phillips, D.M. Barrios, J. Wu, D.Y.M. Leung, A.P. Moy, et al. 2020. Immune checkpoint inhibitor-related dermatologic adverse events. Journal of the American Academy of Dermatology 83: 1255\u20131268.","journal-title":"Journal of the American Academy of Dermatology"}],"container-title":["Inflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10753-025-02281-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10753-025-02281-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10753-025-02281-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T17:12:43Z","timestamp":1762881163000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10753-025-02281-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":52,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["2281"],"URL":"https:\/\/doi.org\/10.1007\/s10753-025-02281-w","relation":{},"ISSN":["1573-2576"],"issn-type":[{"value":"1573-2576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,3]]},"assertion":[{"value":"3 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}